Valuation: Viking Therapeutics, Inc.

Market Cap 3.38B 2.95B 2.78B 2.53B 4.74B 324B 4.76B 33.35B 12.87B 165B 12.7B 12.42B 531B P/E 2026 *
-6.29x
P/E 2027 * -6.83x
Enterprise Value 2.94B 2.57B 2.42B 2.2B 4.12B 282B 4.14B 29.02B 11.2B 144B 11.05B 10.81B 462B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
96.91%
Yield 2026 *
-
Yield 2027 * -
1 day-1.26%
1 week-9.35%
Current month-11.56%
1 month-13.13%
3 months-4.58%
6 months-13.59%
Current year-17.60%
1 week 28.4
Extreme 28.4
32.43
1 month 28.4
Extreme 28.4
35.79
Current year 25.77
Extreme 25.77
42.79
1 year 24.52
Extreme 24.52
43.15
3 years 8.28
Extreme 8.28
99.41
5 years 2.02
Extreme 2.02
99.41
10 years 0.88
Extreme 0.88
99.41
Manager TitleAgeSince
Chief Executive Officer 60 24/09/2012
Director of Finance/CFO 55 04/01/2021
Chief Tech/Sci/R&D Officer 57 11/06/2026
Director TitleAgeSince
Chairman 68 01/05/2015
Chairman 60 24/09/2012
Director/Board Member 53 01/05/2014
Date Insider Type Main position Quantity % Market Cap. Importance
01/08/26 Free

Director

47,133 0.0404%
29/07/26 Sell

Chief Operating Officer

-18,217 0.0157%
29/07/26 Sell

Founder

-148,517 0.1279%
Change 5-day change 1-year change 3-year change Capi.($)
-1.26%-9.35%+11.33%+109.84% 3.38B
-0.31%+5.79%+48.93%+97.53% 70.88B
+0.39%+2.06%+40.91%+78.49% 62.49B
-3.21%-7.27%-17.73%+351.98% 26.21B
+0.50%+7.13%+29.43%+15.48% 26.34B
-2.64%-0.69%-0.26%-11.90% 24.13B
+0.71%+8.03%+27.22%-13.18% 20.72B
-1.26%-7.81%+169.33%+302.38% 15.36B
-0.22%+3.99%+44.28%+173.35% 14.46B
+0.73%+1.71%-7.18%+886.19% 14.25B
Average -0.66%+0.55%+34.63%+199.02% 27.82B
Weighted average by Cap. -0.48%+1.31%+36.20%+147.51%

Financials

2026 *2027 *
Net sales - -
Net income -541M -472M -446M -405M -758M -51.93B -761M -5.34B -2.06B -26.4B -2.03B -1.99B -84.96B -539M -470M -444M -403M -755M -51.75B -759M -5.32B -2.05B -26.31B -2.03B -1.98B -84.65B
Net Debt -439M -383M -362M -328M -615M -42.15B -618M -4.33B -1.67B -21.43B -1.65B -1.61B -68.96B -520M -453M -428M -389M -728M -49.87B -731M -5.13B -1.98B -25.36B -1.95B -1.91B -81.59B
Logo Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
Employees
65
Date Price Change Volume
18/09/26 $28.99 -1.26% 2,671,391
17/09/26 $29.36 -0.54% 2,086,755
16/09/26 $29.52 -1.44% 3,009,486
15/09/26 $29.95 -5.01% 2,807,988
14/09/26 $31.53 -1.41% 1,849,102
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
28.99USD
Average target price
92.39USD
Spread / Average Target
+218.71%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VKTX Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!